Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on EyePoint Pharmaceuticals. The associated price target remains the same with $43.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its upcoming wet AMD therapy, Duravyu. The pivotal data expected in 2026 suggests that Duravyu could significantly impact the treatment landscape, offering a durable solution in a competitive field. The company’s strategic approach to regulatory approval for wet AMD therapies further strengthens its position, potentially reducing associated risks compared to other innovative trial designs.
Additionally, the anticipated clinical trials and readouts in 2026, including the LUGANO and LUCIA trials, are expected to provide critical insights into Duravyu’s efficacy and positioning against existing treatments. The financial health of EyePoint Pharmaceuticals, with substantial cash reserves, also supports its ability to advance these programs effectively, making it an attractive investment opportunity in the healthcare sector.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 31.8% and a 64.13% success rate on recommended stocks.
In another report released on November 10, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.